A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
High urgency

FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List - The National Law Review

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, limiting outsourcing facilities' ability to compound these drugs without individual patient prescriptions.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Compounding outsourcing facilities (503B) and their clients (hospitals, clinics) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication in Federal Register; final rule expected within 6-12 months.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA proposes not to include these GLP-1 drugs on the 503B bulks list, meaning 503B facilities cannot compound them in advance without a patient-specific prescription.

Who it affects

Compounding outsourcing facilities (503B) and their clients (hospitals, clinics)

What you must do

Review current compounding practices for these drugs; prepare to transition to patient-specific compounding or cease production if proposal is finalized.

Deadline

Comment period ends 60 days after publication in Federal Register; final rule expected within 6-12 months.

Source: https://news.google.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?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)